Table 2.
Prevalence of comorbidites between subjects with mild AL, moderate-to-severe AL, and normal lung function
| Comorbidity | Normal n = 11,785 |
AL | p value | |
|---|---|---|---|---|
| Mild n = 469 | Moderate-to-very severe n = 451 | |||
| Men (n = 6,661) | n = 6,010 | n = 257 | n = 394 | |
| Lumg cancer | 9 (0.15) | 3 (1.17) | 7 (1.78) | <0.001 |
| Hypertension | 2,602 (43.29) | 127 (49.42) | 210 (53.30) | 0.064 |
| Diabetes and hyperglycemia | 1,241 (20.65) | 65 (25.29) | 102 (22.62) | 0.012 |
| Dyslipidemia | 2,887 (48.04) | 118 (45.91) | 182 (46.19) | 0.637 |
| MetS (JIS) | 1,009 (16.79) | 44 (17.12) | 84 (21.32) | 0.068 |
| MetS (JCCMS) | 964 (16.04) | 46 (18.11) | 68 (17.26) | 0.611 |
| Ischemic heart disease | 164 (2.73) | 7 (2.72) | 14 (3.55) | 0.627 |
| Osteoporosis | 8 (0.13) | 0 (0) | 1 (0.25) | 0.684 |
| Depression and mental disease | 17 (0.28) | 0 (0) | 1 (0.25) | 0.692 |
| Women (n = 6,044) | n = 5,775 | n = 212 | n = 57 | |
| Lumg cancer | 15 (0.26) | 2 (0.94) | 1 (1.75) | 0.026 |
| Hypertension | 1,886 (32.66) | 97 (45.75) | 25 (43.86) | <0.001 |
| Diabetes and hyperglycemia | 754 (13.06) | 44 (20.75) | 9 (15.79) | 0.005 |
| Dyslipidemia | 2,433 (42.13) | 94 (44.34) | 17 (29.82) | 0.138 |
| MetS (JIS) | 1,024 (17.73) | 51 (24.06) | 9 (15.79) | 0.057 |
| MetS (JCCMS) | 200 (3.46) | 14 (6.60) | 2 (3.51) | 0.054 |
| Ischemic heart disease | 61 (1.06) | 3 (1.42) | 0 (0) | 0.648 |
| Osteoporosis | 316 (5.47) | 19 (8.96) | 6 (10.53) | 0.027 |
| Depression and mental disease | 15 (0.26) | 1 (0.47) | 0 (0) | 0.779 |
Data presented are number (percent)
Ischemic heart disease; including angina pectoris and myocardial infarction Airflow limitation (AL) was dfined as FEV1/FVC < 0.7
Hypertension; antihypertensive medication use or systolic blood pressure ≧ 130 mmHg or diastolc blood pressure ≧ 85 mmHg Diabetes and hypergfycemia; blood glucose-lowerning medication use or elevated fasting glucose ≧ 110 Dyslipidemia; medication use or triglycerides ≧ 150 mg/dl, HDL-C < 40 mg/dl or LDL-C ≧ 140 mg/dl
AL airflow limitation, MetS metabolic syndrome, JIS Joint Interim Statement, JCCMS Japanese Committee of Criteria for MetS